CHICAGO, Jun 03, 2013 (BUSINESS WIRE) -- --- Rapid Onset of Clinical Activity ... MarketWatch (press release) An investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituximab and ... |
